Bioatla Inc
BCAB0.622USD
-0.069-10.00%
收盘 09/19, 16:00（美东）报价延迟15分钟
36.52M总市值
亏损市盈率 TTM
关于 Bioatla Inc 公司
BioAtla, Inc. 是一家临床阶段生物制药公司，专注于开发用于治疗实体瘤癌症的抗体疗法。该公司的候选产品包括 Mecbotamab vedotin (BA3011)、Ozuriftabmab vedotin (BA3021)、BA3071 和 BA3182。其主要候选产品 BA3011 是一种有条件活性的生物制剂 (CAB) 抗体-药物偶联物 (ADC)，靶向蛋白激酶受体 AXL。BA3071 是多种实体瘤类型的潜在治疗剂，包括软组织和骨肉瘤以及非小细胞肺癌 (NSCLC)。BA3021 正在开发一种针对受体酪氨酸激酶（如孤儿受体 2 (ROR2)）的 CAB 抗体药物偶联物。BA3071 是一种 CAB 抗 CTLA-4 抗体，正在开发用于治疗多种实体瘤适应症。 BA3182 设计有 EpCAM 结合域和 CD3 结合域，两个结合域均具有 CAB 活性（Dual-CAB），用于治疗晚期腺癌。
公司简介
公司代码BCAB
公司名称Bioatla Inc
上市日期Dec 16, 2020
CEODr. Jay M. Short, Ph.D.
员工数量61
证券类型Ordinary Share
年结日Dec 16
公司地址11085 Torreyana Road
城市SAN DIEGO
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编92121
电话18585580708
网址https://www.bioatla.com/
公司代码BCAB
上市日期Dec 16, 2020
CEODr. Jay M. Short, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Jay M. Short, Ph.D.
Dr. Jay M. Short, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
2.52M
-0.25%
Dr. Eric L. Sievers, M.D.
Dr. Eric L. Sievers, M.D.
Chief Medical Officer
Chief Medical Officer
407.12K
-0.67%
Mr. Richard A. Waldron
Mr. Richard A. Waldron
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
388.92K
-0.61%
Dr. Lawrence Steinman, M.D.
Dr. Lawrence Steinman, M.D.
Lead Independent Director
Lead Independent Director
144.27K
+19.46%
Dr. Mary Ann Gray, Ph.D.
Dr. Mary Ann Gray, Ph.D.
Independent Director
Independent Director
143.20K
+19.63%
Dr. Susan Moran, M.D.
Dr. Susan Moran, M.D.
Independent Director
Independent Director
118.11K
+24.84%
Mr. Edward L. (Eddie) Williams
Mr. Edward L. (Eddie) Williams
Independent Director
Independent Director
--
--
Mr. Scott A. Smith
Mr. Scott A. Smith
Director
Director
--
--
Ms. Sylvia Mcbrinn
Ms. Sylvia Mcbrinn
Independent Director
Independent Director
--
--
Mr. Christian Vasquez, CPA
Mr. Christian Vasquez, CPA
Chief Accounting Officer, Controller, Corporate Secretary
Chief Accounting Officer, Controller, Corporate Secretary
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Jay M. Short, Ph.D.
Dr. Jay M. Short, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
2.52M
-0.25%
Dr. Eric L. Sievers, M.D.
Dr. Eric L. Sievers, M.D.
Chief Medical Officer
Chief Medical Officer
407.12K
-0.67%
Mr. Richard A. Waldron
Mr. Richard A. Waldron
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
388.92K
-0.61%
Dr. Lawrence Steinman, M.D.
Dr. Lawrence Steinman, M.D.
Lead Independent Director
Lead Independent Director
144.27K
+19.46%
Dr. Mary Ann Gray, Ph.D.
Dr. Mary Ann Gray, Ph.D.
Independent Director
Independent Director
143.20K
+19.63%
Dr. Susan Moran, M.D.
Dr. Susan Moran, M.D.
Independent Director
Independent Director
118.11K
+24.84%
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月19日 周二
更新时间: 8月19日 周二
持股股东
股东类型
持股股东
持股股东
占比
Acorn Capital Advisors, LLC
8.23%
OPOKA Towarzystwo Funduszy Inwestycyjnych S.A.
6.04%
Short (Jay M)
4.30%
The Vanguard Group, Inc.
3.04%
Acadian Asset Management LLC
2.54%
其他
75.85%
持股股东
持股股东
占比
Acorn Capital Advisors, LLC
8.23%
OPOKA Towarzystwo Funduszy Inwestycyjnych S.A.
6.04%
Short (Jay M)
4.30%
The Vanguard Group, Inc.
3.04%
Acadian Asset Management LLC
2.54%
其他
75.85%
股东类型
持股股东
占比
Investment Advisor
21.01%
Individual Investor
11.04%
Hedge Fund
4.12%
Investment Advisor/Hedge Fund
3.99%
Research Firm
0.62%
Private Equity
0.02%
其他
59.21%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
222
25.27M
43.26%
-19.66M
2025Q1
236
24.74M
42.74%
-20.20M
2024Q4
263
32.45M
57.22%
-12.96M
2024Q3
259
29.88M
61.37%
-17.19M
2024Q2
266
34.25M
70.95%
-15.78M
2024Q1
275
36.99M
76.93%
-12.58M
2023Q4
283
37.85M
79.00%
-13.74M
2023Q3
290
39.74M
85.24%
-20.01M
2023Q2
294
41.64M
89.42%
-15.48M
2023Q1
295
41.22M
88.67%
-9.50M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Acorn Capital Advisors, LLC
4.84M
8.28%
+803.07K
+19.92%
May 15, 2025
OPOKA Towarzystwo Funduszy Inwestycyjnych S.A.
3.55M
6.07%
+3.55M
--
Mar 06, 2025
Short (Jay M)
2.53M
4.33%
-6.35K
-0.25%
May 31, 2025
The Vanguard Group, Inc.
1.82M
3.11%
-14.47K
-0.79%
Mar 31, 2025
Acadian Asset Management LLC
1.69M
2.89%
+1.53M
+968.91%
Mar 31, 2025
Tang Capital Management, LLC
1.37M
2.35%
--
--
Mar 31, 2025
Short (Carolyn Anderson)
1.35M
2.32%
--
--
Apr 21, 2025
Smith Scott Andrew
852.35K
1.46%
+23.50K
+2.84%
Jun 18, 2025
Renaissance Technologies LLC
744.83K
1.27%
-84.76K
-10.22%
Mar 31, 2025
Aguja Capital GmbH
750.00K
1.28%
--
--
Feb 28, 2025
查看更多
持股ETF
更新时间: 9月6日 周六
更新时间: 9月6日 周六
机构名称
占比
ProShares UltraPro Russell2000
0%
ProShares Ultra Nasdaq Biotechnology
0%
ProShares Hedge Replication ETF
0%
Proshares Ultra Russell 2000
0%
iShares Micro-Cap ETF
0%
ProShares UltraPro Russell2000
占比0%
ProShares Ultra Nasdaq Biotechnology
占比0%
ProShares Hedge Replication ETF
占比0%
Proshares Ultra Russell 2000
占比0%
iShares Micro-Cap ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
